More intriguingly, in the GSE 145733 cohort, in which gene expression of CD34+ cells was analysed, RUNX1 expression was significantly correlated with blast counts (r = 0.355, p = 0.003) while patients with AML‐MRC had higher RUNX1 expression than those with either MDS‐EB or non‐EB MDS (p = 0.037, Figure 1C), indicating that RUNX1 might play a role during the acute transformation of MDS. Here, RUNX1 is linked to acute myeloid leukemia.